SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has signed an option agreement with Leland Stanford Junior University (“Stanford”) that will add proprietary technology to the Company’s programs.
Help employers find you! Check out all the jobs and post your resume.
